| 1I7G | A: | CRYSTAL STRUCTURE OF THE LIGAND BINDING DOMAIN FROM HUMAN PPAR-ALPHA IN COMPLEX WITH THE AGONIST AZ 242 |
| 1K7L | A:; C:; E:; G: | THE 2.5 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A CO-ACTIVATOR PEPTIDE. |
| 1KKQ | A:; B:; C:; D: | CRYSTAL STRUCTURE OF THE HUMAN PPAR-ALPHA LIGAND-BINDING DOMAIN IN COMPLEX WITH AN ANTAGONIST GW6471 AND A SMRT COREPRESSOR MOTIF |
| 2NPA | A:; C: | THE CRYSTAL STRUCTURE OF THE HUMAN PPARAPLPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A A-HYDROXYIMINO PHENYLPROPANOIC ACID |
| 2P54 | A: | A CRYSTAL STRUCTURE OF PPAR ALPHA BOUND WITH SRC1 PEPTIDE AND GW735 |
| 2REW | A: | CRYSTAL STRUCTURE OF PPARALPHA LIGAND BINDING DOMAIN WITH BMS-631707 |
| 2ZNN | A: | HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST TIPP703 |
| 3ET1 | A:; B: | STRUCTURE OF PPARALPHA WITH 3-[5-METHOXY-1-(4-METHOXY-BENZENESULFONYL)-1H-INDOL-3-YL]-PROPIONIC ACID |
| 3FEI | A: | DESIGN AND BIOLOGICAL EVALUATION OF NOVEL, BALANCED DUAL PPARA/G AGONISTS |
| 3G8I | A: | ALEGLITAZAR, A NEW, POTENT, AND BALANCED PPAR ALPHA/GAMMA AGONIST FOR THE TREATMENT OF TYPE II DIABETES |
| 3KDT | A:; B: | CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL)METHOXY)BENZYL)-N-(METHOXYCARBONYL)GLYCINE |
| 3KDU | A:; B: | CRYSTAL STRUCTURE OF PEROXISOME PROLIFERATOR-ACTIVATEDECEPTOR ALPHA (PPARALPHA) COMPLEX WITH N-3-((2-(4-CHLOROPHENYL)-5-METHYL-1,3-OXAZOL-4-YL)METHOXY)BENZYL)-N-((4-METHYLPHENOXY)CARBONYL)GLYCINE |
| 3VI8 | A: | HUMAN PPAR ALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH A SYNTHETIC AGONIST APHM13 |
| 4BCR | A:; B: | STRUCTURE OF PPARALPHA IN COMPLEX WITH WY14643 |
)
)